Non-Invasive Glymphatic (GF) Monitoring and Recovery Optimization for Warfighter Cognitive Readiness

The Problem

Ensuring sustained cognitive performance and resilience during prolonged missions and extreme operational stress remains a critical and unmet military medical need. Modern combat environments expose warfighters to repeated subconcussive and concussive brain trauma, chronic sleep deprivation, circadian disruption, and limited recovery windows, which are factors that collectively impair decision-making, reaction time, situational awareness, and emotional regulation. These impairments increase the risk of operational errors, accidents, and long-term neurological and psychiatric conditions, including traumatic brain injury (TBI), depression, and cognitive dysfunction. Over the past decade, the glymphatic system, the brain’s endogenous waste clearance mechanism, has emerged as a key biological pathway linking sleep, brain injury, and long-term neurological health. However, operational use of this science has been limited by the lack of non-invasive tools to measure glymphatic function and the absence of deployable interventions to restore function during disrupted sleep or after injury. Without effective solutions, glymphatic dysfunction will continue to degrade force readiness, increase long-term healthcare burden, and compromise mission performance.

Solution & Progress

Applied Cognition, a Silicon Valley based biotechnology company, has developed the GF Monitor, the first non-invasive, ecologically valid device capable of measuring neuro-glymphatic brain function in human subjects. Validated against contrast-enhanced MRI, the current gold standard, the GF Monitor enables real-time assessment of glymphatic activity in environments previously inaccessible to traditional neuroimaging. The system has been deployed in hundreds of overnight studies across sleep clinics, performance laboratories, and emerging field-use environments, generating new insights into how sleep physiology drives clearance of neurotoxic proteins. Complementing this platform, Applied Cognition has developed ACX-02, a fixed-dose combination therapy shown in clinical studies to enhance sleep-linked glymphatic clearance mechanisms. Together, these technologies represent the first integrated capability to both measure and enhance glymphatic function in humans. Since receiving support through MTEC funded initiatives, Applied Cognition has advanced system validation, expanded real-world deployments, and established strategic collaborations supporting continued development of both monitoring and therapeutic solutions for operational use.

Impact & the Role of MTEC

If successful, Applied Cognition’s integrated monitoring and therapeutic platform will strengthen warfighter readiness by enabling continuous assessment and optimization of recovery, cognitive performance, and resilience during prolonged operations. The lightweight, field-deployable GF Monitor enables objective measurement of sleep-linked neurophysiological recovery, supporting informed decisions about readiness and redeployment. Complementing this capability, the ACX-02 therapeutic is designed to enhance recovery during restricted sleep cycles, helping maintain peak operational performance while reducing the risk of both immediate performance degradation and long-term neurological injury. These combined capabilities have the potential to improve operational safety, extend mission endurance, and reduce long-term healthcare burden associated with TBI, depression, and neurodegenerative conditions.

MTEC and its Government sponsor have played an important role in advancing this effort by supporting the development and validation of glymphatic monitoring and recovery technologies, enabling the transition from laboratory-based discovery to operationally relevant deployment and human performance applications. This support has accelerated the maturation of both diagnostic and therapeutic capabilities critical to sustaining cognitive readiness in demanding military environments.